Phibro Animal Health Corporation (PAHC) To Go Ex-Dividend on June 3rd

Phibro Animal Health Corporation (NASDAQ:PAHC) announced a quarterly dividend on Tuesday, May 5th. Shareholders of record on Wednesday, June 3rd will be paid a dividend of 0.12 per share on Wednesday, June 24th. This represents a c) dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Wednesday, June 3rd.

Phibro Animal Health has a payout ratio of 23.9% meaning its dividend is sufficiently covered by earnings. Research analysts expect Phibro Animal Health to earn $3.32 per share next year, which means the company should continue to be able to cover its $0.48 annual dividend with an expected future payout ratio of 14.5%.

Phibro Animal Health Stock Performance

Shares of PAHC stock opened at $30.79 on Monday. The stock’s fifty day moving average price is $48.45 and its two-hundred day moving average price is $45.64. The company has a market cap of $1.25 billion, a PE ratio of 13.21, a P/E/G ratio of 0.47 and a beta of 0.47. Phibro Animal Health has a fifty-two week low of $22.85 and a fifty-two week high of $60.08. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. The firm had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Equities analysts predict that Phibro Animal Health will post 3.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PAHC has been the topic of a number of research analyst reports. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Citigroup reduced their target price on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a report on Friday, February 6th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Finally, Weiss Ratings downgraded Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $38.80.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.